Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Prostatic Neoplasms × fludrocortisone acetate × Clear all

Phase

Status

Active not recruiting 2 Recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

Docetaxel 149 Prednisone 120 Leuprolide 88 bicalutamide 75 enzalutamide 74 Radiotherapy 74 Goserelin 70 Abiraterone Acetate 70 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 51 Magnetic Resonance Spectroscopy 40 Zoledronic Acid 38 Estramustine 31 gallium 68 PSMA-11 30 Flutamide 30 apalutamide 27 abiraterone 27 radium Ra 223 dichloride 25 Gonadotropin-Releasing Hormone 24 Radiosurgery 23 Androgen Antagonists 23 cabazitaxel 22 Surveys and Questionnaires 21 Paclitaxel 20 Dutasteride 20 sipuleucel-T 19 Triptorelin Pamoate 18 Radiation 18 Prednisolone 18 Exercise 18 luprolide acetate gel depot 17

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06554639 2024-10-15

MK-5684-011

Merck Sharp & Dohme LLC

Phase 1 Completed

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡